medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-21-132-137medsovet-2827Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYДекслансопразол МВ в лечении гастроэзофагеальной рефлюксной болезниDexansoprazole MV in the treatment of gastroesophageal reflux diseaseЛеоноваМ. В.LeonovaМ. V.

Леонова Марина Васильевна – доктор медицинских наук, профессор, член-корреспондент РАЕН, клинический фармаколог, член Межрегиональной общественной организации «Ассоциация клинических фармакологов России»

117997, г. Москва, ул. Островитянова, д. 1

Leonova Marina Vasilievna – Dr. of Sci. (Med.), Professor, Corr. Member of RANS, Clinical Pharmacologist, Member of the Interregional Public Organization, Association of Clinical Pharmacologists of Russia

117997, Moscow, 1 Ostrovityanova

anti23@mail.ruАлимоваЭ. Э.AlimovaE. Е.

Алимова Эльмира Эрфановна – кандидат медицинских наук, доцент кафедры клинической фармакологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Alimova Elmira Erfanovna – Cand.of Sci. (Med.), Associate Professor, Department of Clinical Pharmacology, Faculty of General Medicine

117997, Moscow, 1 Ostrovityanova

alimovaee@yandex.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education “Pirogov Russian National Research Medical University” of the Ministry of Health of RussiaRussian Federation201818012019021132137Copyright © Леонова М.В., Алимова Э.Э., 20192019Леонова М.В., Алимова Э.Э.Leonova М.V., Alimova E.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2827

Декслансопразол МВ является R-энантиомером лансопразола и в настоящее время является единственным ингибитором протонного насоса с новой технологией доставки Dual Delayed Release. Фармакокинетика препарата показывает два пика высвобождения в двенадцатиперстной и тонкой кишках; антисекреторное действие показано в дозах 30 и 60 мг, удержание внутрижелудочного рН > 4 более 16,5 ч/сут независимо от времени приема. В клинических исследованиях показано, что декслансопразол МВ обладает высокой эффективностью в заживлении эрозивного эзофагита и контроле симптомов у пациентов с неэрозивной рефлюксной болезнью, поддерживает ремиссию при длительном применении. Эффективен в улучшении симптомов ночной изжоги, связанной с ГЭРБ, при нарушении сна. Декслансопразол МВ имеет аналогичный профиль безопасности и побочных эффектов с лансопразолом.

Dexlensoprazole MB is the R-enantiomer of lansoprazole and is currently the only proton pump inhibitor with the new Dual Delayed Release delivery technology. The pharmacokinetics of the drug shows two peaks of release in the 12-finger and small intestine; antisecretory effect is shown in doses of 30 mg, 60 mg, and retention of intragastric pH > 4 more than 16.5 hours per day; regardless of the time of administration. Clinical studies have shown that dexlansoprazole MB is highly effective in the healing of erosive esophagitis and symptom control in patients with non-erosive reflux disease; maintains remission with prolonged use. Effective in improving the symptoms of night heartburn associated with GERD, with sleep disturbances. Dexlensoprazole MB has a similar safety profile and side effects with lansoprazole.

декслансопразол МВфармакокинетикафармакодинамикаантисекреторная активностьГЭРБэрозивный эзофагитнеэрозивная болезньDexlensoprazole MRpharmacokineticspharmacodynamicsantisecretory activityGERDerosive esophagitisnonerosive diseaseReferencesMoayyedi P., Santana J., Khan M., Preston C., Donnellan C. WITHDRAWN: Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2011; 2: CD003244.Moayyedi P., Santana J., Khan M., Preston C., Donnellan C. WITHDRAWN: Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2011;2: CD003244.Katz P.O., Scheiman J.M., Barkun A.N. Review article: Acid-related disease – What are the unmet clinical needs? Aliment Pharmacol Ther. 2006; 23(Suppl 2): 9–22.Katz P.O., Scheiman J.M., Barkun A.N. Review article: Acid-related disease – What are the unmet clinical needs? Aliment Pharmacol Ther. 2006; 23(Suppl 2): 9–22.Ruigómez A., Johansson S., Wernersson B., Fernández C.O., García R.L.A.. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012; 47(7): 751-61.Ruigómez A., Johansson S., Wernersson B., Fernández C.O., García R.L.A.. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012; 47(7): 751-61.Bell N.J., Burget D., Howden C.W., Wilkinson J., Hunt R.H. Appropriate acid suppression for the management of gastro‐oesophageal reflux disease. Digestion. 1992, 51(Suppl. 1): 59–67.Bell N.J., Burget D., Howden C.W., Wilkinson J., Hunt R.H. Appropriate acid suppression for the management of gastro‐oesophageal reflux disease. Digestion. 1992, 51(Suppl. 1): 59–67.Hunt R.H. Review article: the unmet needs in delayed‐release proton‐pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005, 22(Suppl. 3): 10–19.Hunt R.H. Review article: the unmet needs in delayed‐release proton‐pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005, 22(Suppl. 3): 10–19.Chey W.D., Mody R.R., Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010; 55(12): 3415-22.Chey W.D., Mody R.R., Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010; 55(12): 3415-22.Dean B.B., Gano A.D., Knight K., Ofman J.J., Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004; 2: 656–64.Dean B.B., Gano A.D., Knight K., Ofman J.J., Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004; 2: 656–64.Zhang J.X., Ji M.Y., Song J., Lei H.B., Qiu S., Wang J. et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013; 19(45): 8408-19.Zhang J.X., Ji M.Y., Song J., Lei H.B., Qiu S., Wang J. et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013; 19(45): 8408-19.Sachs G., Shin J.M., Howden C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23(Suppl 2): 2-8.Sachs G., Shin J.M., Howden C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23(Suppl 2): 2-8.Miner P.J., Katz P.O., Chen Y., Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five‐way crossover study. Am J Gastroenterol. 2003; 98: 2616–20.Miner P.J., Katz P.O., Chen Y., Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five‐way crossover study. Am J Gastroenterol. 2003; 98: 2616–20.Fass R., Murthy U., Hayden C.W., Malagon I.B., Pulliam G., Wendel C., Kovacs T.O. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventionaldose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000; 14(12): 1595-603.Fass R., Murthy U., Hayden C.W., Malagon I.B., Pulliam G., Wendel C., Kovacs T.O. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventionaldose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000; 14(12): 1595-603.Zhang H., Yang Z., Ni Z., Shi Y. A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of dastroesophageal reflux disease. Gastroenterol Res Pract. 2013; Article ID 9865963.Zhang H., Yang Z., Ni Z., Shi Y. A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of dastroesophageal reflux disease. Gastroenterol Res Pract. 2013; Article ID 9865963.Fujiwara Y., Arakawa T., Fass R. Gastroesophageal reflux disease and sleep disturbances. J Gastroenterol. 2012; 47(7): 760-9.Fujiwara Y., Arakawa T., Fass R. Gastroesophageal reflux disease and sleep disturbances. J Gastroenterol. 2012; 47(7): 760-9.Nzeako U.C., Murray J.A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther. 2002; 16: 1309–16.Nzeako U.C., Murray J.A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther. 2002; 16: 1309–16.Белоусов Ю.Б., Леонова М.В. Лекарственные формы с модифицированным высвобождением и системы доставки лекарств: особенности фармакокинетики и клиническая эффективность. М.: «Литтерра», 2011: 440-444.Belousov Yu.B., Leonova M.V. Modified release dosage forms and drug delivery systems: pharmacokinetic features and clinical efficacy. M.: Litterra, 2011: 440-444 (In Russ).Frye J.W., Peura D.A. Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015; 11: 1649–56.Frye J.W., Peura D.A. Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015; 11: 1649–56.Katsuki H., Yagi H., Arimori K., Nakamura C., Nakano M., Katafuchi S. et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996, 13: 611–5.Katsuki H., Yagi H., Arimori K., Nakamura C., Nakano M., Katafuchi S. et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996, 13: 611–5.Metz D.C., Vakily M., Dixit T., Mulford D. Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009; 29: 928–37.Metz D.C., Vakily M., Dixit T., Mulford D. Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009; 29: 928–37.Vakily M., Zhang W., Wu J., Atkinson S., Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009; 25: 627–38.Vakily M., Zhang W., Wu J., Atkinson S., Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009; 25: 627–38.Wu J., Vakily M., Witt G., Mulford D. TAK-390MR vs. lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol. 2007; 102(suppl 2): S124 (abstract).Wu J., Vakily M., Witt G., Mulford D. TAK-390MR vs. lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol. 2007; 102(suppl 2): S124 (abstract).Lee R.D., Mulford D., Wu J., Atkinson S.N. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010; 31: 1001-11.Lee R.D., Mulford D., Wu J., Atkinson S.N. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010; 31: 1001-11.Sharma P., Shaheen N.J., Perez M.C., Pilmer B.L., Lee M., Atkinson S.N., Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel delayed-release formulation – results from two randomized controlled studies. Aliment Pharmacol Ther. 2009; 29: 731-41.Sharma P., Shaheen N.J., Perez M.C., Pilmer B.L., Lee M., Atkinson S.N., Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel delayed-release formulation – results from two randomized controlled studies. Aliment Pharmacol Ther. 2009; 29: 731-41.Fass R., Chey W.D., Zakko S.F, Andhivarothai N., Palmer R.N., Perez M.C., Atkinson S.N. Clinical trial: the effect of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009; 29: 1261-72.Fass R., Chey W.D., Zakko S.F, Andhivarothai N., Palmer R.N., Perez M.C., Atkinson S.N. Clinical trial: the effect of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009; 29: 1261-72.Farup C., Kleinman L., Sloan S., Ganoczy D., Chee E., Lee C., Revicki D. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001; 161: 45–52 .Farup C., Kleinman L., Sloan S., Ganoczy D., Chee E., Lee C., Revicki D. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001; 161: 45–52 .Mody R., Bolge S.C., Kannan H., Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol. 2009; 7: 953–9.Mody R., Bolge S.C., Kannan H., Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol. 2009; 7: 953–9.Fass R., Johnson D.A., Orr W.C., Han C., Mody R., Stern K.N. et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011; 106: 421-31.Fass R., Johnson D.A., Orr W.C., Han C., Mody R., Stern K.N. et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011; 106: 421-31.Fass R., Inadomi J., Han G., Mody R., O’Neil J., Perez M.C. Maintenance of heartburn relief after stepdown from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012; 10: 247-63.Fass R., Inadomi J., Han G., Mody R., O’Neil J., Perez M.C. Maintenance of heartburn relief after stepdown from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012; 10: 247-63.Dickman R., Maradey-Romero C., Gingold-Belfer R., Fass R.. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015; 21: 309–19.Dickman R., Maradey-Romero C., Gingold-Belfer R., Fass R.. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015; 21: 309–19.Metz D.C., Howden C.W., Perez M.C., Larsen L., O’Neil J., Atkinson S.N. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009; 29: 742–54.Metz D.C., Howden C.W., Perez M.C., Larsen L., O’Neil J., Atkinson S.N. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009; 29: 742–54.Peura D.A., Metz D.C., Dabholkar A.H., Paris M.M., Yu P., Atkinson S.N. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009; 30: 1010-21.Peura D.A., Metz D.C., Dabholkar A.H., Paris M.M., Yu P., Atkinson S.N. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009; 30: 1010-21.Zhang W., Wu J., Atkinson S.N. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol. 2009; 49(4): 444–454.Zhang W., Wu J., Atkinson S.N. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol. 2009; 49(4): 444–454.Ивашкин В.Т., Маев И.В., Трухманов А.С., Баранская Е.К., Дронова О.Б., Зайратьянц О.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерол. гепатол. колопроктол. 2017; 27(4): 75-95.Ivashkin V.T., Maev I.V., Trukhmanov A.S., Baranskaya E.K., Dronova O.B., Zayratyants O.V., et al. Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of gastroesophageal reflux disease. Ros. Zhurn. Gastroenterol. Gepatol. Koloproktol 2017; 27 (4): 75-95 (In Russ).

The authors declare that there are no conflicts of interest present.